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Background: Fractalkine (CX3CL1) promotes migration and adhesion of lymphocytes and monocytes to inflamed
tissues. Prior studies show a role for CX3CL1 in atherosclerosis. The relationship between inflammatory cytokines,
cholesterol, and CX3CL1 levels in human subjects without known coronary artery disease is not well characterized.
The goal of our study was to assess baseline CX3CL1 levels, and after modulation of cholesterol levels by statins to
determine if CX3CL1 is linked to cholesterol levels or inflammatory stimuli.
Methods: We performed a blinded, randomized hypothesis generating study in human subjects without known
coronary artery disease treated sequentially with three statins of differing potencies. Fractalkine (CX3CL1), GM-CSF,
VEGF-A, other chemokines, and lipid levels were measured. Mechanistic studies of CX3CL1 induction by LDL cholesterol
and TNFα in cultured human endothelial cells were performed using real-time PCR.
Results: Therapy with statins reduced total and LDL cholesterol levels as expected. CX3CL1 levels were significantly
reduced from no statin control levels (89.9 ± 18.5 pg/mL) after treatment with atorvastatin (60.0 ± 7.8 pg/mL),
pravastatin (54.2 ± 7.0 pg/mL) and rosuvastatin (65.6 ± 7.3 pg/mL) (χ2(2) = 17.4, p≤ 0.001). Cholesterol is not a known
regulator of CX3CL1. We found GM-CSF (r2 = 0.524; p < 0.005) and VEGF-A (r2 = 0.4; p < 0.005) levels were highly and
positively correlated with CX3CL1. Total (r2 = 0.086) and LDL cholesterol (r2 = 0.059) levels weakly correlated with
CX3CL1 levels. Finally, we tested whether LDL cholesterol could induce CX3CL1, GM-CSF, and VEGF-A in human
endothelial cells, versus TNFα. LDL cholesterol alone resulted in small, non-significant increases in CX3CL1 and GM-CSF,
while TNFα resulted in > 10-fold induction.
Conclusions: Our findings suggest that while statins suppress CX3CL1 levels, inflammatory cytokines may be the major
regulator of CX3CL1 levels rather than cholesterol itself. Additional studies in a larger patient population are needed to
confirm these findings, determine if CX3CL1 levels reflect inflammation levels, and potentially add to standard risk
factors in prediction of atherosclerotic disease events.Background
Chemokines are small peptides that form a chemical
gradient which guides migration of inflammatory cells to
sites of disease. Fractalkine (CX3CL1) is a structurally
distinct chemokine. It is a membrane bound glycoprotein
with a chemokine domain atop a mucin-like stalk and un-
like other CX3C family chemokines, signals through a sin-
gle Gαi-linked receptor: CX3CR1 [1]. Membrane bound
fractalkine is induced most abundantly in endothelial cells
by several inflammatory cytokines, promoting integrin
independent adhesion of CD16+ CX3CR1+ monocytes [2]* Correspondence: tcimato@buffalo.edu
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reproduction in any medium, provided the origand CD8+ CX3CR1+ cytotoxic T lymphocytes [3]. CX3
CL1 expression on inflamed endothelium attracts NK cells
and cytotoxic T cells, resulting in lysis of neighboring
endothelial cells [4]. Additional sources of CX3CL1 in-
clude monocytes, macrophages, fibroblasts and dendritic
cells in synovial tissue, indicating a role for CX3CL1 in
rheumatologic diseases as well [5]. These findings link
CX3CL1 expression directly to recruitment of inflamma-
tory cell types. CX3CL1 is also released from the cell
membrane in an active soluble form by proteolysis via
ADAM10 and 17. Release of soluble CX3CL1 creates a
chemokine gradient guiding chemotaxis of inflammatory
cells to sites of injury [5].
Several lines of evidence indicate a role for CX3CL1 in
the pathogenesis of atherosclerosis. Both CX3CL1−/−is is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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model of atherosclerosis showed a significant reduction
in macrophage recruitment to the vessel wall and de-
creased atherosclerotic lesion formation compared to
normal animals [6,7]. In humans, CX3CR1 polymor-
phisms in the coding region of the gene are a genetic
risk factor for early onset coronary artery disease,
strongly supporting a mechanistic role for CX3CL1 in
the pathogenesis of atherosclerosis [8,9]. Both CX3CL1
levels, and CD3+CD8+ CX3CR1+ T cell levels increase
in patients with chronic coronary artery disease [10] and
acute coronary syndromes with plaque rupture [11],
strongly supporting a link between CX3CL1 and athero-
sclerosis in humans.
A clear link between CX3CL1 levels, polymorphisms,
and coronary artery disease in humans is well defined.
While hypercholesterolemia is a known risk factor for
coronary artery disease events, most subjects with acute
coronary syndromes have mildly elevated cholesterol
levels [12]. However, the levels of CX3CL1 in asymp-
tomatic subjects without known coronary disease have
not been studied. Prior studies indicate that CX3CL1
levels are significantly increased in both chronic coron-
ary artery disease and acute coronary syndromes
[10,11]. The effect of cholesterol lowering therapy on
CX3CL1 levels in subjects with chronic coronary artery
disease is less clear as the high potency statin, atorva-
statin 80 mg daily reduced CX3CL1 levels, while a
lower potency statin, simvastatin 20 mg daily did not
decrease CX3CL1 [10]. Given the clear role of hyper-
cholesterolemia as a risk factor for atherosclerotic dis-
eases, and the functional role of CX3CL1 in atherosclerosis
and plaque rupture, we aimed to determine if CX3CL1
levels varied with cholesterol levels in human subjects
without known atherosclerotic disease. In this study we de-
termined baseline CX3CL1 levels in human subjects with-
out known coronary disease and after modulation of
cholesterol levels using different statins to determine if
CX3CL1 levels are linked to cholesterol levels or other in-
flammatory stimuli.Table 1 Clinical data
Mean values
Baseline Atorvastatin Pravastat
Age 43.4 ± 12.5
BMI 24.9 ± 7.2
Framingham Risk Score 1.7 ± 0.5
Total Cholesterol (mg/dL) 210.5 ± 27.6 138.5 ± 28.9 160.6 ± 28
LDL Cholesterol (mg/dL) 136.2 ± 22.9 68.2 ± 12.1 88.7 ± 24
HDL Cholesterol (mg/dL) 53.5 ± 12.9 54.1 ± 18.6 54.5 ± 13.
C-Reactive Protein (mg/L) 1.1 ± 1.3 1.05 ± 1.1 0.95 ± 0.8Methods
Patient consent for participation
Our research protocol was reviewed and approved by the
University at Buffalo Intramural Review Board for Health
Sciences research (Approval Number: MED5980509B).
Informed consent to undergo the study protocol was
obtained in writing from each participant according to the
principles expressed in the Declaration of Helsinki. Our
study was organized as an observational trial as no direct
health outcomes were to be measured.Characteristics of study subjects
The study population consisted of 12 adult subjects (7
males and 5 females) with no active medical problems.
Study subjects were screened for the absence of chronic
health disorders including hypercholesterolemia with add-
itional cardiovascular risk factors, cancer, diabetes, chronic
liver or kidney disease [13]. The baseline characteristics of
the study population were reported previously [13] and
are shown in Table 1. The age of the cohort was 43.4 ±
12.5 years, had a body mass index of 24.9 ± 7.2, and
were at low risk for atherosclerotic disease events with
a Framingham Risk Score of 1.7 ± 0.5. Prior to statin
treatment the mean total cholesterol level was 210.5 ±
27.6 mg/dL, LDL cholesterol 136.2 ± 22.9 mg/dL, HDL
cholesterol 53.5 ± 12.9 mg/dL. The cohort had a low
index of inflammation as the C-reactive protein level was
1.1 ± 1.3 mg/L. Two of the study subjects had treated
hypertension. None of our study subjects had disease states
known to increase CX3CL1 levels including common vari-
able immunodeficiency [14], granulomatosis [15], congest-
ive heart failure [16], and did not smoke [17].Study protocol
Study subjects were randomized to drug regimen groups
using a block randomization design. The investigators
were blinded to which treatment subjects were receiving.
The workflow of the experimental protocol is summa-
rized in Figure 1. Study subjects underwent a baseline± SD p-value (statin vs. baseline)
in Rosuvastatin Atorvastatin Pravastatin Rosuvastatin
.9 154.2 ± 21.0 <0.0001 <0.0001 <0.0001
83.3 ± 12.7 <0.0001 <0.0002 <0.0001
1 55.3 ± 15.3 NS NS NS
1.3 ± 1.5 NS NS NS
Figure 1 Flow chart of experimental design.
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panel (total, HDL, and LDL cholesterol, and triglycerides)
and C-reactive protein were determined by the Kaleida
Health pathology laboratory. The plasma fraction was also
retained from each blood draw and frozen at −80°C for
chemokine and cytokine assays. Subjects were then
treated for two weeks with one of three different HMG-
CoA reductase inhibitors (pravastatin 80 mg daily, atorva-
statin 80 mg daily, or rosuvastatin 10 mg daily). At the
end of the two-week statin treatment, venous blood was
sampled again to obtain the lipid panel, C-reactive protein
level, and blood samples for cytokine analysis. Subjects
were subsequently given a four-week statin free period. At
the end of the four week statin-free period, venous blood
was sampled again to determine if serum lipids returned
to within 5% of their pre-statin levels. In subjects where
cholesterol levels did not recover to within 5% of thebaseline lipid levels, an additional four-week statin free
period was provided before resuming statin therapy to
avoid effects of overlap between drugs. Three study sub-
jects required extension of the statin free period for an
additional four weeks for serum lipid levels to return to
within 5% of their baseline lipid levels. Following this
period, the next HMG-CoA reductase inhibitor in the
randomization scheme was given for two weeks. The same
protocol was repeated for statin drugs two and three until
study completion. All twelve subjects completed treat-
ment with the three statin medications.
Cytokine and chemokine assays
Plasma levels of fractalkine (CX3CL1), GM-CSF, FLT3 lig-
and, GRO alpha, Interleukin-3, Interleukin-6, Interleukin-
8, macrophage inflammatory protein-1 (MIP-1/CCL3),
monocyte chemotactic protein-1 (MCP-1), stromal de-
rived growth factor-1 (SDF-1), and VEGF-A were mea-
sured with a Luminex Human Cytokine assay (Millipore)
per the manufacturer’s instructions by the Roswell Park
Cancer Institute Laboratory of Flow Cytometry. For Lumi-
nex based assays, known concentrations of CX3CL1, GM-
CSF, and VEGF-A were measured in triplicate to generate
standard curves using a non-linear five-parameter curve
fit using the nCal package in R [18]. The reliable lower
assay limits for each were: CX3CL1-39.5 pg/mL, GM-CSF
3.02 pg/mL, VEGF-A 36.6 pg/mL. The inter-assay %CV
for CX3CL1 was 5.13, and the intra-assay %CV for
CX3CL1 was 5.85. Plasma cytokine levels from human
subjects before and after statin treatment were measured
in singulate. Interleukin-17 levels were measured with an
ELISA (R&D Systems).
Real time PCR analysis
Human umbilical vein endothelial cells (Lonza, passages
3–5) were grown to 80% confluence in EGM-2 medium
(Lonza) on type I collagen coated culture dishes. Where
indicated, cells were incubated for 18 hours in human
LDL cholesterol (100 μg/mL; Biomedical Technologies,
Stoughton, MA, USA) and/or atorvastatin (100 nM;
Sigma Scientific). TNFα (1 μg/mL; R&D Systems) was
then added for an additional 18 hours after LDL choles-
terol or atorvastatin treatment where indicated. Cells
were then washed in warm PBS and lysed in QIAzol
solution (Qiagen), and RNA was extracted following the
manufacturer’s protocol. RNA quality was assessed by
OD260/280 using a Nanodrop spectrophotometer. Total
RNA was reverse transcribed using SuperScript III Re-
verse Transcriptase with oligo-dT primers (Invitrogen).
Real-time PCR analysis was performed using SYBR
green and Taq DNA polymerase (Qiagen) on a Bio-Rad
CFX96 Connect Real-Time PCR Detection System. PCR
primers for CX3CL1, GM-CSF, ICAM, VCAM, CX3CR1,
and VEGF-A were obtained from Qiagen. RT-PCR data
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tive changes in transcript levels.
Statistical analysis
Regression analyses were tested for significance using
Pearson’s correlation. Heat map representations of RT-
PCR data were compiled using R. Significant differ-
ences in CX3CL1, GM-CSF, and VEGF-A plasma levels
between statin therapies were assessed using a non-
parametric Friedman’s two-way ANOVA by ranks with a
Bonferroni correction for multiple comparisons. Differ-
ences in CX3CL1, ICAM, VCAM-1, and VEGF-A tran-
script levels in response to LDL cholesterol incubation or
TNFα versus untreated cells were measured by a one-way
ANOVA with a Bonferroni correction for multiple com-
parisons. RT-PCR data for GM-CSF was analyzed by one-
way ANOVA with a Games-Howell post-hoc test due to
unequal variances between treatment groups. Numerical
data stated in the manuscript text represent mean ± stand-
ard error of the mean. Statistical analysis was performed
using SPSS software.
Results
Effects of statins on CX3CL1 levels in human subjects
without known heart disease
To understand whether CX3CL1 levels vary with choles-
terol levels or other factors in humans, we assessed
CX3CL1 levels in human subjects without known coron-
ary disease and used HMG-CoA reductase inhibitors
(statins) of varying potencies to modulate cholesterol
levels. The baseline characteristics of the study cohort
were published previously [13], and are shown in Table 1.Figure 2 Effect of HMG-CoA reductase inhibitors on fractalkine (CX3C
(CX3CL1) were determined in plasma of adult human subjects (n = 12) withou
80 mg daily, Pravastatin 80 mg daily, or Rosuvastatin 10 mg daily for two wee
error of the mean. * indicate significant differences versus no statin therapy, pBaseline serum lipids revealed an average total choles-
terol of 210.5 ± 27.6 mg/dL (range 168 to 282 mg/dL)
and an average LDL cholesterol of 136.2 ± 22.9 (range
114 to 205). The total and LDL cholesterol levels
spanned the normal and hypercholesterolemic range.
Therapy with statins reduced total and LDL cholesterol
levels as expected, demonstrating appropriate drug effect
[13]. CX3CL1 levels were significantly reduced from no
statin control levels (89.9 ± 18.5 pg/mL) after treatment
with atorvastatin (60.0 ± 7.8 pg/mL), pravastatin (54.2 ±
7.0 pg/mL) and rosuvastatin (65.6 ± 7.3 pg/mL) (χ2(2) =
17.4, p ≤ 0.001; see Figure 2), indicating statins downreg-
ulate CX3CL1 levels in adult human subjects.
GM-CSF and VEGF-a levels are positively correlated with
CX3CL1 levels
We next sought to elucidate factors regulating CX3CL1
after statin therapy. CX3CL1 is induced by inflammatory
cytokines including interferon-γ, interleukin-6, and TN
Fα [5]. Cholesterol however, is not a known regulator of
CX3CL1. We surveyed the levels of inflammatory cyto-
kines in the plasma of our cohort before and after statin
therapy. We found FLT3 ligand, Interleukin-3, Inter
leukin-6, and Macrophage inflammatory protein-1 (MIP-
1/CCL3) were undetectable in most subjects, indicating a
lack of typical CX3CL1 inducers in our cohort of asymp-
tomatic human subjects. We identified correlations be-
tween CX3CL1 plasma levels and granulocyte macro
phage-colony stimulating factor (GM-CSF), VEGF-A,
stromal cell-derived factor-1/CXCL12 (SDF-1), GROα/
CXCL1, monocyte chemotactic protein-1/CCL2 (MCP-1),
interleukin-8/CXCL8 (IL-8), neutrophil counts, andL1) plasma levels in adult human subjects. Levels of Fractalkine
t known coronary artery disease after no therapy (None), Atorvastatin
ks. Results shown are the mean values and error bars indicate standard
≤ 0.001.
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test significant correlations with CX3CL1 levels in human
blood (Table 2). We found that GM-CSF (r2 = 0.524; p <
0.005; Figure 3) and VEGF-A (r2 = 0.4; p < 0.005; Figure 4)
levels were highly and positively correlated with CX3CL1.
To explore why GM-CSF and VEGF-A were significantly
correlated with CX3CL1 levels, we evaluated if statins de-
creased the concentrations of GM-CSF and VEGF-A, and
if GM-CSF and VEGF-A levels correlated with total, LDL,
or HDL cholesterol values. We found that all statin ther-
apies significantly decreased both GM-CSF (Figure 5) and
VEGF-A levels (Figure 6), but there was no significant
correlation between GM-CSF or VEGF-A levels with total,
LDL, or HDL cholesterol. These findings suggest that the
effect of statins on GM-CSF and VEGF-A levels are more
likely driven by suppression of inflammatory signaling
rather than a reduction in cholesterol levels.
SDF-1/CXCL12, LDL cholesterol, MCP-1/CCL2, total
cholesterol, and IL-8/CXCL8 levels all showed statisti-
cally significant associations with CX3CL1 levels.
GROα/CXCL1, circulating neutrophil levels, and HDL
cholesterol levels (Figure 7) were negatively correlated
with CX3CL1 levels. We did not find significant correl-
ation between CX3CL1 levels and C-reactive protein,
IL-17, CD34+ HSPC levels, VEGF-C or G-CSF. Inter-
estingly, the shared biological function of GM-CSF,
VEGF-A, SDF-1, GROα, and IL-8 lies in regulation of
chemotaxis and response to inflammation. These find-
ings suggest that CX3CL1, along with several other
factors involved in response to inflammation and
chemotaxis of inflammatory cell types are modulated















CD34+ CD45 dim 0.003
Interleukin-17 0.00008LDL cholesterol itself weakly induces CX3CL1, GM-CSF,
and VEGF-a while statins suppress their expression in
human endothelial cells
To determine whether CX3CL1, GM-CSF and VEGF-A
levels are modulated by LDL cholesterol itself or by in-
flammatory cytokines, and how statins may affect
CX3CL1, GM-CSF and VEGF-A expression, we incu-
bated human umbilical vein endothelial cells with loaded
with LDL cholesterol with or without atorvastatin (100
nM) for 18 hours. Then TNFα was added for an add-
itional 18 hours. Real-time PCR analysis was performed
to measure changes in the levels of CX3CL1, GM-CSF,
and VEGF-A. ICAM and VCAM-1 are induced by TNFα
treatment of endothelium via an NFκB dependent mech-
anism [19], and were positive experimental controls. Ex-
perimental results are summarized in Figure 8 showing
log 2 fold changes in gene expression relative to un-
treated endothelial cells. We found that LDL cholesterol
alone resulted in small increases in CX3CL1, ICAM1,
and VCAM1, but were not significant due to a high de-
gree of variability between experimental replicates. GM-
CSF expression was modestly decreased by incubation
with LDL cholesterol. LDL cholesterol incubation alone
caused modest but significant increase in VEGF-A (0.1
fold increase versus untreated cells; p ≤ 0.05). TNFα
treatment resulted in > 10-fold increases in transcripts of
CX3CL1 (99.0 ± 0.11 fold vs. untreated; p < 0.0005), and
GM-CSF (106.1 ± 1.3 fold vs. untreated; p < 0.0005).
Positive controls for TNFα treatment, ICAM1 (39.7 ±
0.06 vs. untreated; p < 0.0005) and VCAM1 (82.8 ± 0.53
vs. untreated; p < 0.0005), also showed > 10-fold induc-
















Figure 3 Correlation of fractalkine (CX3CL1) levels and GM-CSF levels in blood of adult human subjects. Fractalkine (CX3CL1) and GM-CSF
plasma levels measured in all subjects (n = 12 subjects) before and after statin treatments. p≤ 0.005 by Pearson’s correlation.
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p < 0.006) transcript levels. Incubation with TNFα and
LDL cholesterol together resulted in modest, but not
significant, augmentation of expression of CX3CL1,
GM-CSF, VCAM1, ICAM1, and VEGF-A compared with
TNFα treatment alone. Finally, addition of atorvastatin
(100 nM) significantly reduced induction of ICAM1,
VCAM1, CX3CL1 and GM-CSF by both LDL choles-
terol and TNFα. In conclusion, LDL cholesterol alone
did not substantially augment CX3CL1 or GM-CSF
transcript levels in human endothelial cells in vitro.
TNFα coordinately increased transcript levels of CX3CL1
and GM-CSF, and the addition of LDL cholesterol mod-
estly increased both transcripts, while atorvastatinFigure 4 Correlation of fractalkine (CX3CL1) levels and VEGF-A levels in
plasma levels measured in all subjects (n = 12 subjects) before and after statinsignificantly reduced CX3CL1 and GM-CSF expression.
The findings support a model where inflammatory cyto-
kines intersect with cholesterol levels to augment expres-
sion of a module of inflammatory response factors
including CX3CL1 and GM-CSF, and statins inhibit their
induction.
Discussion
Our study establishes the following findings: 1) In a
cohort of human subjects without known coronary ar-
tery disease and cholesterol levels that span the normal
and hypercholesterolemic range, CX3CL1, GM-CSF, and
VEGF-A levels are significantly reduced by multiple sta-
tin therapies (atorvastatin, pravastatin and rosuvastatin).blood of adult human subjects. Fractalkine (CX3CL1) and VEGF-A
treatments. p≤ 0.005 by Pearson’s correlation.
Figure 5 Effect of HMG-CoA reductase inhibitors on GM-CSF plasma levels in adult human subjects. Levels of GM-CSF were determined
in plasma of adult human subjects without known coronary artery disease (n = 12) after no therapy (None), Atorvastatin 80 mg daily, Pravastatin
80 mg daily, or Rosuvastatin 10 mg daily for two weeks. Results shown are the mean values and error bars indicate standard error of the mean.
*indicate significant differences versus no statin therapy, p≤ 0.005.
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statin effects on LDL cholesterol, and negatively correlate
with HDL cholesterol levels. 3) CX3CL1 levels are signifi-
cantly correlated with GM-CSF, VEGF-A, IL-8/CXCL8,
and SDF-1/CXCL12, suggesting that this combination of
chemokine factors is coordinately regulated. 4) In vitro,
LDL cholesterol alone did not significantly induce CX3CL1
or GM-CSF, but had minor effects on VEGF-A expression;
CX3CL1 and GM-CSF were coordinately induced by TNFαFigure 6 Effect of HMG-CoA reductase inhibitors on VEGF-A plasma le
plasma of adult human subjects without known coronary artery disease (n
80 mg daily, or Rosuvastatin 10 mg daily for two weeks. Results shown are
*indicate significant differences versus no statin therapy, p≤ 0.05.in endothelial cells, likely due to a shared mechanism regu-
lating their expression.
Prior studies of CX3CL1 in human subjects focused on
cohorts with chronic coronary artery disease, or acute cor-
onary syndromes. Our study uniquely shows positive cor-
relation between CX3CL1 plasma protein levels and LDL
cholesterol and negative correlation with HDL cholesterol.
The implied connection between LDL cholesterol levels
and CX3CL1 plasma levels is important in that CX3CL1vels in adult human subjects. Levels of VEGF-A were determined in
= 12) after no therapy (None), Atorvastatin 80 mg daily, Pravastatin
the mean values and error bars indicate standard error of the mean.
Figure 7 Correlation of fractalkine (CX3CL1) levels and HDL cholesterol levels in blood of adult human subjects. Fractalkine (CX3CL1)
and HDL cholesterol levels measured in all subjects (n = 12) before and after statin treatments. p≤ 0.025 by Pearson’s correlation.
Figure 8 Heat map plot of real-time PCR data of GM-CSF, fractalkine (CX3CL1), VCAM1, ICAM1, and VEGF-A in human endothelial cells
stimulated with LDL cholesterol and TNFα. Expression of each transcript was determined and normalized to GAPDH expression. Levels of each
transcript in untreated cells were arbitrarily set to zero. Data shown represent log 2-fold change in expression relative to untreated cells. Results
are an average of three experimental replicates. Significant differences are noted in the Results section of the manuscript.
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augments chemotaxis of inflammatory cells to sites of in-
jury. Evidence from CX3CL1−/− [6], CX3CR1−/− [7], and
CX3CR1 pharmacologic inhibition studies in mice [20]
with a background of hypercholesterolemia mechanistic-
ally tied CX3CL1 to atherosclerosis. Taken together, these
results, the mechanistic findings in animal models of ath-
erosclerosis, and our correlative findings between LDL
cholesterol and CX3CL1 levels in humans, suggest that
CX3CL1 may represent a biomarker of the inflammatory
component of atherosclerosis and potentially define sub-
jects at increased risk for atherosclerotic disease events.
Future studies will aim to test the relationship between
CX3CL1 levels and atherosclerotic disease events and test
the hypothesis that targeting CX3CL1 levels may reduce
the number of atherosclerosis disease events.
Prior studies of CX3CL1 in human subjects showed
substantial increases in CX3CL1 serum protein levels in
the setting of chronic coronary artery disease and unstable
angina. Damas and co-workers did not report a relation-
ship between CX3CL1 protein levels and cholesterol but
did show a significant positive correlation between
CX3CR1 mRNA levels in peripheral blood mononuclear
cells and LDL cholesterol levels [10]. In contrast to our
findings, Damas and co-workers found that atorvastatin
but not simvastatin decreased plasma levels of CX3CL1,
while we found effectiveness of all statins tested in redu-
cing CX3CL1 plasma levels. This may be explained by a
relative lack of inflammation in our study cohort in com-
parison to the study by Damas et al. which focused on
subjects with chronic coronary artery disease. Franco and
co-workers identified significant positive correlations be-
tween CX3CL1 plasma levels and IL-6, apolipoprotein-B,
LDL cholesterol, and insulin in a community based cohort
of 3306 middle aged women, lending additional support
to our findings in a much smaller patient population [21].
Interestingly, we found CX3CL1 levels to have a high
positive correlation with GM-CSF and VEGF-A. We were
unable identify any clear connection between GM-CSF
and CX3CL1 in the literature. Our in vitro experiments
indicate that both CX3CL1 and GM-CSF may be regu-
lated coordinately by inflammatory cytokines such as
TNFα, as both transcripts were equivalently induced. We
observed that CX3CL1 protein levels were not correlated
1:1 with GM-CSF in human plasma. One possible reason
for the lack of unity between the two proteins is GM-CSF
mRNA is post-transcriptionally regulated and either rap-
idly degraded or stabilized depending on the stimulating
factors [22], potentially decreasing translation of GM-CSF
mRNA to protein. Interestingly, GM-CSF signaling sig-
nificantly increases IL-1β secretion [23] and IL-1β is
implicated in atherosclerosis in animal studies [24].
Neutralization of IL-1β is the subject of a current clinical
trial (NCT01327846) to prevent recurrent cardiovascularevents in patients with a prior myocardial infarction [25].
The example of GM-CSF mediated induction of IL-1β, a
known mediator of atherosclerosis, provides an illustra-
tion of how CX3CL1 and GM-CSF may have multiple
downstream effects to augment atherosclerosis.
We also noted a significant positive correlation between
CX3CL1 and VEGF-A levels in adult human subjects
(Figure 3; r2 = 0.4; p ≤ 0.005). In addition to recruiting in-
flammatory cells to sites of inflammation, CX3CL1 stimu-
lates angiogenesis through expression of VEGF-A in
endothelial cells, promoting increased proliferation and an-
giogenic activity in vivo [26]. Our RT-PCR experiments did
not reveal that VEGF-A was significantly induced by
stimulation with the inflammatory cytokine TNFα, and
LDL cholesterol minimally increased VEGF-A in human
endothelial cells. The correlation we identified between
CX3CL1 and VEGF-A levels in the blood of adult human
subjects may be tied to CX3CL1 induction of VEGF-A as
previously described [26]. Additionally, we found that ther-
apy with all three statins reduced VEGF-A levels in our
study cohort, which is in agreement with prior studies in
subjects with hypercholesterolemia [27], chronic coronary
artery disease [28], and acute myocardial infarction [29].
We noted significant positive correlations between
CX3CL1 and IL-8 levels. IL-8/CXCL8 is a proinflamma-
tory cytokine that is produced by endothelial cells,
monocytes, and vascular smooth muscle cells, and plays
an important role in the migration of monocytes into
the subendothelial space [30]. This represents a crucial
step in initiation of atherosclerosis. In the EPIC-Norfolk
Perspective Population Study, elevated blood levels of
IL-8 in 785 healthy men and women predicted future
coronary artery disease events after adjustment for trad-
itional risk factors, C-reactive protein, and white cell
count. IL-8 is also known as neutrophil chemotactic factor,
and interestingly we noted positive correlation between
CX3CL1 levels and neutrophil counts in our study. Ele-
vated neutrophil counts themselves have been implicated
as predictors of ischemic heart disease events in several
epidemiologic studies [31-34]. Animal model studies indi-
cate that hypercholesterolemia increases neutrophil counts
and that neutrophils infiltrate arteries in the early stages of
atherosclerosis [35]. Collectively, the signals that elevate
CX3CL1 levels coincide with increased IL-8 and neutrophil
levels, which are mechanistically tied to atherosclerosis.
In conclusion, we found that CX3CL1, GM-CSF, and
VEGF-A levels are significantly decreased by statin therapy
in adult human subjects without known coronary artery
disease. CX3CL1 levels correlate with several cytokine and
chemokine mediators of inflammation and inflammatory
cell mobilization, as well as cholesterol levels. Mechan-
istically, CX3CL1 and GM-CSF transcripts were not
significantly induced by cholesterol alone, but by the
inflammatory cytokine TNFα. Statin therapy suppressed
Cimato and Palka Clinical and Translational Medicine 2014, 3:14 Page 10 of 11
http://www.clintransmed.com/content/3/1/14their protein levels in the blood of adult human sub-
jects, and transcript levels in human endothelial cells
in vitro. The effect of statins on CX3CL1 and GM-CSF
levels may not be completely attributed to reduction in
cholesterol levels based on our findings. Our work indi-
cates that CX3CL1 and GM-CSF may represent putative
biomarkers of inflammation associated with atheroscler-
osis, such as C-reactive protein, but are mechanistically
tied to atherosclerosis based on the well established find-
ings in animal models of atherosclerosis. Future studies
will examine the relationship between CX3CL1 levels and
atherosclerotic disease events, and assess whether target-
ing CX3CL1 levels would represent an effective means to
reduce atherosclerosis disease events.
Conclusions
Statin therapy significantly reduces the levels of CX3CL1
in the blood stream of human subjects without known
coronary artery disease. CX3CL1 levels are weakly, but
positively correlated with total and LDL cholesterol
levels, and negatively correlated with HDL cholesterol
levels. Remarkably GM-CSF and VEGF-A levels were
highly correlated to CX3CL1 levels. In cultured human
endothelial cells, LDL cholesterol alone did not result in
significant induction of CX3CL1 mRNA, but TNFa coor-
dinately induced CX3CL1 and GM-CSF mRNAs. Our
findings suggest that while statins may suppress CX3CL1
levels, inflammatory cytokines may be the major regulator
of CX3CL1 levels rather than cholesterol itself. Additional
studies are needed to confirm these findings, and deter-
mine if CX3CL1 levels reflect inflammation levels.
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